245 related articles for article (PubMed ID: 10023734)
1. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
Axen KV; Li X; Sclafani A
Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
[TBL] [Abstract][Full Text] [Related]
2. Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099).
Russell JC; Graham SE; Dolphin PJ
Metabolism; 1999 Jun; 48(6):701-6. PubMed ID: 10381143
[TBL] [Abstract][Full Text] [Related]
3. The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats.
Fukaya N; Mochizuki K; Tanaka Y; Kumazawa T; Jiuxin Z; Fuchigami M; Goda T
Eur J Pharmacol; 2009 Dec; 624(1-3):51-7. PubMed ID: 19818342
[TBL] [Abstract][Full Text] [Related]
4. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
5. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
[TBL] [Abstract][Full Text] [Related]
6. The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats.
DeBouno JF; Michaelis OE; Tulp OL
Gen Pharmacol; 1993 Mar; 24(2):509-15. PubMed ID: 8482529
[TBL] [Abstract][Full Text] [Related]
7. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats.
Goda T; Suruga K; Komori A; Kuranuki S; Mochizuki K; Makita Y; Kumazawa T
Br J Nutr; 2007 Oct; 98(4):702-10. PubMed ID: 17537288
[TBL] [Abstract][Full Text] [Related]
8. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
9. Effect of miglitol administration to non-insulin-dependent diabetic rats.
Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE
Gen Pharmacol; 1998 Jan; 30(1):125-9. PubMed ID: 9457493
[TBL] [Abstract][Full Text] [Related]
10. Ca2+ deficiency, selective alpha-glucosidehydrolase inhibition, and insulin secretion.
Salehi A; Lundquist I
Am J Physiol; 1993 Jul; 265(1 Pt 1):E1-9. PubMed ID: 7687825
[TBL] [Abstract][Full Text] [Related]
11. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Heinz G; Komjati M; Korn A; Waldhäusl W
Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
[TBL] [Abstract][Full Text] [Related]
12. Miglitol, a new alpha-glucosidase inhibitor.
Sels JP; Huijberts MS; Wolffenbuttel BH
Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
[TBL] [Abstract][Full Text] [Related]
13. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor].
Kuboyama N; Hayashi I; Yamaguchi T
Nihon Yakurigaku Zasshi; 2006 Mar; 127(3):223-32. PubMed ID: 16651808
[No Abstract] [Full Text] [Related]
15. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
Johnston PS; Coniff RF; Hoogwerf BJ; Santiago JV; Pi-Sunyer FX; Krol A
Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185
[TBL] [Abstract][Full Text] [Related]
16. The effects of low-dose Bay-m-1099 (Miglitol) on serum lipids and liver enzyme activity of obese and obese-diabetic corpulent rats.
Tulp OL; Szepesi B; Michaelis OE; DeBouno JF
Comp Biochem Physiol C Comp Pharmacol Toxicol; 1991; 99(1-2):241-6. PubMed ID: 1675969
[TBL] [Abstract][Full Text] [Related]
17. In vitro study of the effect of miglitol on carbohydrate digestion and intestinal metabolism in normal and non-insulin-dependent diabetic rats.
Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE
Can J Physiol Pharmacol; 1996 Nov; 74(11):1196-203. PubMed ID: 9028577
[TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]